Alexandra Glucksmann
REGENXBIOAbout Alexandra Glucksmann
Alexandra Glucksmann, Ph.D., age 66, has served as an independent director of REGENXBIO since May 2018. She is currently President & CEO of Sensorium Therapeutics (private), Senior Advisor at Scenic Biotech BV (private), and serves on the Supervisory Board of TME Pharma NV (oncology). She holds a B.S. in Bacteriology (University of Wisconsin–Madison) and a Ph.D. in Molecular Genetics & Cell Biology (University of Chicago), with a postdoctoral fellowship at MIT. Her background includes company formation, executive operating roles, and scaling R&D and operations at multiple biotech companies.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Cedilla Therapeutics, Inc. | President & CEO; Director | Apr 2018 – Nov 2022 | Private biotech; led company formation/execution as CEO |
| Third Rock Ventures, LLC | Entrepreneur-in-Residence | Oct 2017 – Mar 2018 | Company formation focus |
| Editas Medicine, Inc. | Founding employee; Chief Operating Officer | Oct 2013 – Mar 2017 | Public biotech; operational build-out in CRISPR gene editing |
| Cerulean Pharma Inc. | Founding employee; SVP, Research & Business Operations | Sep 2006 – Jun 2013 | Public biotech; built research and business ops |
| Taconic Biosciences, Inc. | Director | Aug 2006 – May 2015 | Board service at preclinical models provider |
External Roles
| Organization | Role | Status/Focus |
|---|---|---|
| Sensorium Therapeutics | President & CEO | Private biotech (neuropsychiatry) |
| Scenic Biotech BV | Senior Advisor | Private biotech |
| TME Pharma NV | Supervisory Board Member | Biotech focused on aggressive cancers |
Board Governance
- Independence: The Board determined Dr. Glucksmann is independent under Nasdaq standards (only the CEO, Chairman, and Allan Fox are non‑independent).
- Committee assignment (2024): Compensation Committee member (8 meetings in 2024).
- Board attendance: The Board met 8 times in 2024; each director attended at least 75% of Board and committee meetings.
- Executive sessions: Independent directors meet in regularly scheduled executive sessions.
- Lead Independent Director: Daniel Tassé (appointed July 1, 2024) provides defined independent board leadership.
- Compensation governance: The Compensation Committee uses Willis Towers Watson as an independent advisor (independence affirmed; no conflicts).
Fixed Compensation
- 2024 non‑employee director cash retainers:
- Board member: $45,000; Lead Independent Director: $25,000; Chairman: $35,000. Committee fees: Audit Chair $20,000 / member $10,000; Compensation Chair $15,000 / member $7,500; Nominating Chair $10,000 / member $5,000. Paid quarterly and pro‑rated for partial years.
- 2024 director compensation (Alexandra Glucksmann):
Year Fees Earned ($) Stock Awards ($) Option Awards ($) Total ($) 2024 52,500 206,245 68,737 327,481
Performance Compensation
- Annual equity grants for non‑employee directors: Aggregate $275,000 value; 75% non‑statutory stock options and 25% RSUs; options vest monthly over 12 months; RSUs vest in full on first anniversary; both fully vest upon change in control.
- Initial equity grant for new directors: Aggregate $550,000; 75% options (36‑month monthly vesting) and 25% RSUs (1/3 annually over 3 years); full vesting on change in control.
Other Directorships & Interlocks
- Current outside boards: Supervisory Board of TME Pharma NV. No disclosed interlocks or cross‑board relationships that create compensation committee interlocks; the Company discloses no Compensation Committee interlocks or insider participation.
- Related party transactions: None in 2024 above $120,000 involving directors, officers, 5% holders, or their affiliates/family members.
Expertise & Qualifications
- Scientific/operational leadership in biotech (company formation; COO at Editas; SVP R&D/business ops at Cerulean).
- Board‐level compensation governance (member of Compensation Committee).
- Academic credentials: B.S. (UW–Madison), Ph.D. (UChicago), postdoc (MIT).
Equity Ownership
- Beneficial ownership (as of April 1, 2025):
Holder Shares Beneficially Owned % of Outstanding Notes Alexandra Glucksmann, Ph.D. 123,956 <1% Includes options to purchase 112,670 shares exercisable or exercisable within 60 days and 4,790 RSUs vesting within 60 days. - Outstanding/unvested equity (as of Dec 31, 2024):
Metric Amount Aggregate unvested RSUs 4,790 Aggregate options outstanding 112,670 - Stock ownership policy/pledging/hedging: The Company prohibits hedging and short sales; pledging requires prior approval.
Governance Assessment
- Board effectiveness and independence: Independent director since 2018 with relevant operating and formation experience; serves on Compensation Committee, which is fully independent and advised by an independent consultant—supportive of pay discipline and board oversight.
- Attendance and engagement: Met the Company’s minimum attendance threshold (≥75%); Board met eight times in 2024 with regular independent executive sessions—positive engagement signal.
- Alignment and incentives: Director pay uses balanced cash retainer plus time‑based option/RSU mix; annual equity awards are modestly front‑loaded but vest over one year (options monthly, RSUs after one year), supporting retention and alignment; CoC vesting is standard for directors.
- Ownership “skin in the game”: Beneficial ownership is under 1% of shares outstanding, typical for a non‑employee director; equity primarily via options/RSUs (112,670 options; 4,790 unvested RSUs).
- Conflicts and related parties: No related‑party transactions disclosed for 2024; Compensation Committee interlocks absent; strong insider trading and anti‑hedging/pledging policy.
Red Flags: None disclosed—no related party transactions, no attendance concerns, no hedging/pledging exceptions reported. Monitor potential time commitments given external roles, though no conflict is disclosed and independence is affirmed.